Embecta Corp. (EMBC)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$5.12-7.75%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Broken: Primary pillar broken — Revenue reaches about $1.025 billion next quarter: FY26 revenue guidance mid $1.02B vs target ~$1.02B.
Embecta completed the acquisition of Owen Mumford to expand its product range. The company targets about $1.025 billion revenue and 22.75% profit margin next quarter. It is cutting costs and buying back shares to improve value. The dividend cut to $0.01 per share boosts financial flexibility.
Revenue fell 14.4% last quarter and EPS missed by 35.7%. Guidance was cut and credit rating downgraded. Analysts expect only 3% revenue growth and have lowered EPS estimates. The recent selloff and rating cut show financial stress.
The market prices in a weak near-term outlook with about 3% revenue growth and lowered EPS. Our fair value is around $8.93, reflecting cautious optimism. We see risk from execution and financial health despite the cheap valuation.
Breaks if: Dividend rises above $0.05 or buyback program stalls
Breaks if: Acquisition integration delays or failure to realize synergies
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on healthcare. The current thesis state is intact, supported by strong recent financial performance and ongoing management priorities.
The market currently prices EMBC as cheap compared to its peers, reflecting a low expectations gap. However, there is a fragility in earnings quality, suggesting that the market does not fully account for potential execution risks.
Management is making steady progress on key priorities, including the integration of Owen Mumford and brand transitions. Recent financial performance has been strong, but there is a near-term risk of earnings misses due to the company's smaller size and erratic earnings history.
The thesis hinges on several factors, including the ability to maintain guidance after a recent raise and the performance of sector bellwethers. Additionally, broader economic conditions, such as job growth and recession fears, could impact EMBC's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Finalize the acquisition of Owen Mumford to expand product portfolio and strengthen B2B drug delivery platform.
Breaks if: Operating margin falls below 20% next quarter
Conduct a comprehensive review of the cost structure and organizational footprint to identify efficiencies.
Breaks if: Revenue falls below $1.0 billion next quarter
Finalize the acquisition of Owen Mumford to expand product portfolio and strengthen B2B drug delivery platform.
Overall, EMBC's trajectory appears stable, but it faces elevated risks that could affect its fundamentals. Not investment advice.